Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein.
Virus Res
; 194: 200-10, 2014 Dec 19.
Article
en En
| MEDLINE
| ID: mdl-25451066
The recent outbreak of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) infection has led to more than 800 laboratory-confirmed MERS cases with a high case fatality rate (â¼35%), posing a serious threat to global public health and calling for the development of effective and safe therapeutic and prophylactic strategies to treat and prevent MERS-CoV infection. Here we discuss the most recent studies on the structure of the MERS-CoV spike protein and its role in virus binding and entry, and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit, particularly the receptor-binding domain (RBD), and the S2 subunit, especially the HR1 region, of the MERS-CoV spike protein. We then look ahead to future applications of these viral entry/fusion inhibitors, either alone or in combination with specific and nonspecific MERS-CoV replication inhibitors, for the treatment and prevention of MERS-CoV infection.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Acoplamiento Viral
/
Internalización del Virus
/
Glicoproteína de la Espiga del Coronavirus
/
Coronavirus del Síndrome Respiratorio de Oriente Medio
Límite:
Humans
Idioma:
En
Revista:
Virus Res
Asunto de la revista:
VIROLOGIA
Año:
2014
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos